AstraZeneca EBITDA 2010-2024 | AZN
AstraZeneca annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- AstraZeneca EBITDA for the quarter ending September 30, 2024 was $3.923B, a 21.23% increase year-over-year.
- AstraZeneca EBITDA for the twelve months ending September 30, 2024 was $14.879B, a 9.45% increase year-over-year.
- AstraZeneca 2023 annual EBITDA was $13.58B, a 47.02% increase from 2022.
- AstraZeneca 2022 annual EBITDA was $9.237B, a 21.76% increase from 2021.
- AstraZeneca 2021 annual EBITDA was $7.586B, a 8.72% decline from 2020.
AstraZeneca Annual EBITDA
(Millions of US $) |
| 2023 |
$13,580 |
| 2022 |
$9,237 |
| 2021 |
$7,586 |
| 2020 |
$8,311 |
| 2019 |
$6,686 |
| 2018 |
$7,140 |
| 2017 |
$6,713 |
| 2016 |
$7,259 |
| 2015 |
$6,966 |
| 2014 |
$5,419 |
| 2013 |
$8,295 |
| 2012 |
$10,666 |
| 2011 |
$15,345 |
| 2010 |
$14,235 |
| 2009 |
$13,630 |
AstraZeneca Quarterly EBITDA
(Millions of US $) |
| 2024-09-30 |
$3,923 |
| 2024-06-30 |
$4,025 |
| 2024-03-31 |
$4,370 |
| 2023-12-31 |
$2,561 |
| 2023-09-30 |
$3,236 |
| 2023-06-30 |
$3,732 |
| 2023-03-31 |
$4,051 |
| 2022-12-31 |
$2,575 |
| 2022-09-30 |
$2,579 |
| 2022-06-30 |
$1,896 |
| 2022-03-31 |
$2,187 |
| 2021-12-31 |
$1,900 |
| 2021-09-30 |
$1,114 |
| 2021-06-30 |
$1,880 |
| 2021-03-31 |
$2,692 |
| 2020-12-31 |
$2,284 |
| 2020-09-30 |
$1,972 |
| 2020-06-30 |
$1,994 |
| 2020-03-31 |
$2,061 |
| 2019-12-31 |
$2,220 |
| 2019-09-30 |
$1,473 |
| 2019-06-30 |
$1,220 |
| 2019-03-31 |
$1,773 |
| 2018-12-31 |
$2,739 |
| 2018-09-30 |
$1,549 |
| 2018-06-30 |
$1,447 |
| 2018-03-31 |
$1,405 |
| 2017-12-31 |
$1,793 |
| 2017-09-30 |
$1,804 |
| 2017-06-30 |
$1,541 |
| 2017-03-31 |
$1,575 |
| 2016-12-31 |
$3,123 |
| 2016-09-30 |
$1,639 |
| 2016-06-30 |
$890 |
| 2016-03-31 |
$1,607 |
| 2015-12-31 |
$1,804 |
| 2015-09-30 |
$1,741 |
| 2015-06-30 |
$1,639 |
| 2015-03-31 |
$1,782 |
| 2014-12-31 |
$672 |
| 2014-09-30 |
$1,392 |
| 2014-06-30 |
$1,807 |
| 2014-03-31 |
$1,548 |
| 2013-12-31 |
$2,014 |
| 2013-09-30 |
$2,094 |
| 2013-06-30 |
$2,139 |
| 2013-03-31 |
$2,048 |
| 2012-12-31 |
$2,728 |
| 2012-09-30 |
$2,901 |
| 2012-06-30 |
$2,378 |
| 2012-03-31 |
$2,659 |
| 2011-12-31 |
$3,137 |
| 2011-09-30 |
$4,805 |
| 2011-06-30 |
$3,476 |
| 2011-03-31 |
$3,927 |
| 2010-12-31 |
$4,136 |
| 2010-09-30 |
$3,008 |
| 2010-06-30 |
$3,299 |
| 2010-03-31 |
$3,792 |
| 2009-12-31 |
$3,738 |
| 2009-09-30 |
$3,608 |
| 2009-06-30 |
$3,001 |
| 2009-03-31 |
$3,283 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$199.805B |
$45.811B |
|
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
|
